Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 219-956-7 | CAS number: 2582-30-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 50
- Absorption rate - dermal (%):
- 50
- Absorption rate - inhalation (%):
- 100
Additional information
In accordance with point 8.8.1 of column 1 (Standard Information Required), Annex VIII of REACH (Regulation EC No. 1907/2006), assessment of the toxicokinetic behaviour of the substance is performed to the extent that can be derived from the relevant available information. A toxicokinetic assessment was performed based on the available physical-chemical data and toxicological information available. Further testing for the assessment of toxicokinetic behaviour is omitted on this basis.
Introduction
Aminouanidium hydrogen carbonate (CAS 2582 -30 -1) is an organic yellow odourless crystalline powder.
No experimental studies of the absorption, metabolism, distribution, or elimination of aminoguanidium hydrogen carbonate (“the substance”) in mammals are available. Information is utilized from existing toxicology studies on the substance, or for other very similar materials, and this data is used to infer, as far as possible, the potential toxicokinetics of the substance.
Physicochemical properties
Systemic availability of the substance depends on its ability to be absorbed across body surfaces. Factors that affect this process include water solubility, lipophilicity (measured by the partition coefficient, Kow), degree of ionization (the dissociation constant, pKa), and molecular size. Aminoguanidium hydrogen carbonate has a molecular weight of 135 and a water solubility of 5 g/L.
Absorption
Oral absorption
The acute oral LD50was greater than 5000 mg/kg bw in an oral gavage study. All rats dosed with 3100 mg/kg of the test substance tolerated the treatment without clinical signs or mortality. All rats dosed with 5000 mg/kg showed sedation and poor general condition within 2 to 6 days after application of the test substance and 4/10 rats died.
In an OECD 421 reproductive toxicity screening study, treatment with the substance at dose levels up to 1000 mg/kg was associated with decreased food consumption, body weights/body weight change and decreased relative and absolute thymus weights. At 1000 mg/kg bw/day, there was also signs of chronic nephropathy and hypertrophy of the kidney tubules as well as hepatocellular hypertrophy in females (NOAEL 300 mg/kg/day in males and 88 mg/kg bw/day in females) suggesting that some absorption took place.
Lower MW components of the substance are likely more readily absorbed than the higher MW components.
The physical chemical properties do not preclude absorption. In the absence of quantitative information, 50% bioavailability following oral administration is assumed for the purposes of human risk assessment.
Dermal absorption
The acute dermal LD50for aminoguanidium hydrogen carbonate was greater than 50000 mg/kg bw in acute dermal toxicity studies, with no clinical signs, effects on body weight or gross abnormalities at necropsy. An in vivo skin irritation study with the substance also showed no toxicity to the test system; however the substance was a skin sensitizer in the LLNA. As the substance did not appear to show systemic effects in the dermal study, it is not likely that dermal absorption was extensive.
Lower MW components of the substance are likely be more readily absorbed than the higher MW components.
For the purposes of risk assessment however, estimation of mammalian dermal absorption is made in accordance with principles adopted by the EFSA guidance on estimating dermal absorption of pesticide active substances (EFSA, 2012). On this basis, dermal absorption is estimated at 50% for undiluted substance, which is considered conservative.
Inhalation absorption
Aminoguanidinium hydrogen carbonate is a solid therefore, absorption through inhalation is unlikely. However, using the REACH principles, inhalation absorption was considered 100% for the calculation of DNELs while oral and dermal absorption were considered 50% each.
Distribution, Metabolism and Elimination
QSAR predictions show that the parent compound is hydrolysed to an intermediate which is further hydrolized and acetylated to form three metabolites which are ultimately eliminated by phase two metabolism.
Conclusion
For the purposes of human risk assessment oral absorption of the substance is estimated at 50% and dermal absorption is estimated at 50%. Inhalation absorption is considered 100%. All DNELs are calculated using an oral OECD 421 study. Therefore, the DNELs for inhalation and dermal exposure will be very conservative.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
